The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Related Articles

The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Curr Urol Rep. 2017 Jul;18(7):50

Authors: Kauffmann G, Liauw SL

Abstract
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician.
RECENT FINDINGS: The benefit of ADT on biochemical control is maintained with dose-escalated RT according to recently reported phase III studies. Furthermore, there is now prospective, randomized evidence to support the addition of ADT to RT in the post-prostatectomy setting. ADT continues to play an important role for prostate cancer patients receiving dose-escalated RT. Future research is needed to identify subgroups most likely to benefit from this combination.

PMID: 28589396 [PubMed - indexed for MEDLINE]

http://ift.tt/2r5saQv